Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix's Shares Jump 30 Percent in June to Lead GWDN Index

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Affymetrix climbed 30 percent in June after the firm announced early in the month that Frank Witney had rejoined the company, replacing Kevin King as president and CEO.

Affymetrix, which is currently trading at a 52-week high, led all shares in the GenomeWeb Daily News Index.

Two other firms, Exact Sciences (+15 percent) and Caliper Life Sciences (+13 percent), also rose in the double digits in an otherwise down month for many of the stocks in the Index.

Exact's stock climbed in the past two weeks. Wedbush Securities recently initiated coverage on the firm with an "Outperform" rating and a $10 price target.

Rosetta Genomics had the steepest decline among the stocks that lost ground for the month. Rosetta fell around 33 percent in June and is down 69 percent for the year.

Among the other stocks that dropped significantly during the month were Nanosphere (-29 percent), Accelr8 (-24 percent), and Vermillion (-24 percent).

Overall, the GWDN Index was down nearly 2 percent, matching the drop for both the Nasdaq and Nasdaq Biotech Index. The Dow Jones Industrial Average lost 1 percent.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.